Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Abreu, I. Silveira, J. P. Ferreira, S. Rocha, P. Leuschner, J. Correia (Porto, Portugal). Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy. Eur Respir J 2014; 44: Suppl. 58, 4691

Member's Comments

No comment yet.

Related content which might interest you: Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014 Frequency of multidrug resistant pathogens in healthcare associated pneumonia Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Monitoring of antimicrobial resistance respiratory strains of streptococcus pneumoniae Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Pseudomonas aeruginosa pneumonia in the community Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Factors associated with mortality in ventilator associated pneumonia of multidrug resistant acinetobacter baumannii Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 ICU acquired pneumonia due to pseudomonas aeruginosa with and without multidrug resistance Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014